MENU
LNTH
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

LNTH stock forecast, quote, news & analysis

Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes... Show more

LNTH
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
A.I.Advisor
a Summary for LNTH with price predictions
Sep 11, 2026

LNTH's Stochastic Oscillator is sitting in oversold zone for 1 day

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for LNTH just turned positive on August 24, 2026. Looking at past instances where LNTH's MACD turned positive, the stock continued to rise in 38 of 47 cases over the following month. The odds of a continued upward trend are 81%.

Following a +0.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where LNTH advanced for three days, in 271 of 334 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

LNTH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LNTH as a result. In 63 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LNTH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.

The Aroon Indicator for LNTH entered a downward trend on August 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. LNTH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 47 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.

The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.990) is normal, around the industry mean (46.728). P/E Ratio (23.983) is within average values for comparable stocks, (93.360). LNTH's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.931). LNTH has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (4.263) is also within normal values, averaging (176.516).

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -5%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 30%. SXTC experienced the highest price growth at 15%, while GELS experienced the biggest fall at -22%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 4%. For the same stocks of the Industry, the average monthly volume growth was -4% and the average quarterly volume growth was -33%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 64
Price Growth Rating: 56
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: -17 (-100 ... +100)
View a ticker or compare two or three
LNTH
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a manufacturer of medical imaging products

Industry PharmaceuticalsGeneric

Profile
Details
Industry
Medical Specialties
Address
201 Burlington Road
Phone
+1 978 671-8001
Employees
1193
Web
https://www.lantheus.com
LNTH's Stochastic Oscillator is sitting in oversold zone for 1 day